Food

 

Just Published: "Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021"



15.11.2017 00:56:30 - Fast Market Research recommends "Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021" from TechNavio, now available

(live-PR.com) - YEAR-END RESEARCH SALE!
- This report might qualify for up to a 30% DISCOUNT if purchased before the end of 2017
- More details at www.fastmr.com/prod/1303071_global_graft_vs_host ..

Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing

 

GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.

Technavio's analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

* Americas
* APAC
* EMEA

Technavio's report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

* Bristol-Myers Squibb
* Novartis
* Pfizer
* F. Hoffmann-La Roche

Other prominent vendors

* Abbott
* AbbVie
* Allergan
* Anterogen
* Astellas Pharma
* Athersys
* Baxter
* Caladrius
* Cellular Biomedicine Group
* Cipla
* Eisai
* Eli Lilly
* GlaxoSmithKline
* Glenmark
* Helsinn Healthcare
* Heron Therapeutics
* Incyte Corporation
* IPCA Laboratories
* Kadmon Holdings
* Lupin
* Osiris Therapeutics
* RedHill
* Sanofi
* Shire
* Sun Pharmaceutical Industries
* Takeda Pharmaceutical
* ViaCyte

Market driver

* Increased prevalence of cancer
* For a full, detailed list, view our report

Market challenge

* Off-label use of drugs
* For a full, detailed list, view our report

Market trend

* Inorganic growth strategies
* For a full, detailed list, view our report

Key questions answered in this report

* What will the market size be in 2021 and what will the growth rate be?
* What are the key market trends?
* What is driving this market?
* What are the challenges to market growth?
* Who are the key vendors in this market space?
* What are the market opportunities and threats faced by the key vendors?
* What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Bristol-Myers Squibb, Novartis, Pfizer, F. Hoffmann-La Roche, bbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.

Browse our complete collection of Medical Devices research reports at www.fastmr.com/catalog/browse.aspx?category=18&a ..

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)


Author:
Bill Thompson
e-mail
Web: http://www.fastmr.com
Phone: 1.413.485.7001


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Live-PR.com Contact Us